<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705626</url>
  </required_header>
  <id_info>
    <org_study_id>TRAP 08-2012</org_study_id>
    <nct_id>NCT01705626</nct_id>
  </id_info>
  <brief_title>Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)</brief_title>
  <acronym>TRAP2-1</acronym>
  <official_title>Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR-FAP): An International, Multicenter, Epidemiological Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An International, multicenter, epidemiological observational study investigating the
      prevalence of Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR-FAP) in
      participants with small fiber polyneuropathy of no obvious etiology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transthyretin-related Familial Amyloid Polyneuropathy (TTR-FAP) is an autosomal dominant,
      progressive neurodegenerative disease, with fatal outcome occurring within ten years after
      onset. Familial amyloid polyneuropathy (FAP) associated with mutations in the transthyretin
      (TTR) gene is the most common form of genetic amyloidosis. It accounts several thousand cases
      worldwide, with Val30Met mutation identified in most patients and with endemic foci in
      Portugal, Sweden and Japan.

      TTR FAP is caused by the systemic deposition of amyloidogenic variants of the transthyretin
      protein ((Ttr) in the extra-cellular space of tissues and result in disruption of organ
      function.The typical presentation of TTR-FAP is a progressive sensory-motor polyneuropathy,
      which usually begins with loss of thermal and pain sensation in the feet, slowly ascends up
      the limbs and is associated with variable autonomic disturbances and extra-neurological
      manifestations (especially a cardiomyopathy).

      The goal of the TRAP2.1 Study is to investigate the prevalence of Transthyretin-Related
      Familial Amyloidotic Polyneuropathy (TTR-FAP) in a cohort of 500 subjects with small fiber
      polyneuropathy of no obvious etiology, based on the subject's clinical presentation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epidemiological analysis of prevalence of the TTR FAP in participants with small fiber polyneuropathy of no obvious etiology.</measure>
    <time_frame>3 years</time_frame>
    <description>Dry Blood Spot (DBS) samples will be genetically validated via combination of Next-Generation Sequencing (the mutation will be confirmed by Sanger sequencing) and the Multiplex ligation-dependent probe amplification (MLPA) of TTR gene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishment of a biomarker in TTR-positive cohort</measure>
    <time_frame>3 years</time_frame>
    <description>Samples carrying a mutation in the TTR gene will be biochemically analyzed via liquid chromatography multiple reaction monitoring MS and compared with a merged control cohort, in order to establish TTR mutation-specific biomarker/s.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Polyneuropathy, Amyloid</condition>
  <condition>Neuropathic Pain</condition>
  <condition>Cardiac Failure</condition>
  <condition>Orthostatic Hypotension</condition>
  <condition>Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>Participants diagnosed with small fiber polyneuropathy</arm_group_label>
    <description>Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with small fiber polyneuropathy of no obvious etiology.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent is obtained from the participant

          -  The participant is aged between 18 and 85 years of age

          -  The participant is diagnosed with small fiber polyneuropathy of no obvious etiology

          -  The participant has no diagnosis of alcoholism, according to International Guidelines

          -  The participant has not undergone chemotherapy for carcinoma

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  The participant is younger than 18 years or older than 85 years of age

          -  The etiology of the small fiber polyneuropathy is clearly determined

          -  The participant has a diagnosis of alcoholism, according to International Guidelines

          -  The participant has undergone chemotherapy for carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Snezana Skobalj, MD</last_name>
    <phone>+49 (0)38180113591</phone>
    <email>snezana.skobalj@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, Abteilung für Neurologie</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffi Topakian, MD</last_name>
      <phone>+43 (0)7242415</phone>
      <phone_ext>2686</phone_ext>
      <email>Raffi.Topakian@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Raffi Topakian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pécs, Department of Neurology</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Endre Pal, MD</last_name>
      <phone>+36 (0)72535900</phone>
      <email>pal.endre@pte.hu</email>
    </contact>
    <investigator>
      <last_name>Endre Pal, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Department of Neurology</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Vescei, MD</last_name>
      <phone>+36 (0)62545351</phone>
      <email>vecsei.laszlo@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Laszlo Vescei, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Skopje, Department of Neurology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University Medical College, Department of Neurology</name>
      <address>
        <city>Kraków</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Dziedzic, Prof.Dr.</last_name>
      <phone>+48 (0)124248600</phone>
      <email>dziedzic@cm-uj.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Tomasz Dziedzic, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Belgrade, Clinical Center of Serbia, Neurology Clinic, Neuropathy Center</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zorica Stević, Prof. Dr.</last_name>
      <phone>+ 381 (0)668301257</phone>
      <email>zstevic05@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zorica Stević, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara, Department of Neurology</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Kostić-Dedić, Prim. Dr.</last_name>
      <phone>+381 (0)113810702</phone>
      <email>svetlana.kostic.dedic@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sanja Jevdjić, Dr.</last_name>
      <email>sanja.jevdjic@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Svetlana Kostić-Dedić, Prim.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Niš, Department of Neurology</name>
      <address>
        <city>Niš</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordana Djordjević, Prof. Dr.</last_name>
      <phone>+381 (0)18506906</phone>
      <email>gordanadjor@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gordana Djordjević, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Dr. Djordje Joanović&quot;</name>
      <address>
        <city>Zrenjanin</city>
        <zip>23000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Damjan, MD</last_name>
      <phone>+381 (0)23513306</phone>
      <email>dr.igor.damjan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Svetlana Milićević-Kuručki, MD</last_name>
      <email>svetlanamilicevic@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Igor Damjan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Cuenca Hernandez, MD</last_name>
      <phone>+34 (0)911918105</phone>
      <email>raquel.cuenca@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Eva Martinez Acebes</last_name>
      <email>eva.martineza@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Raquel Cuenca Hernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <zip>20700</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jose Poza Aldea, MD</last_name>
      <phone>+34 (0)943007539</phone>
      <email>rafaelj.esteban@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Jose Poza Aldea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Hungary</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.centogene.com/clinical-studies/transthyretin-related-familial-amyloidotic-small-fiber-polyneuropathy.html</url>
    <description>Related info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy</keyword>
  <keyword>TTR FAP</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

